M. Péchevis

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.

H. Glick, F. Antoñanzas, W. Edmunds, 2002, PharmacoEconomics.

Economic Evaluation of Vaccination Programmes

H. Glick, F. Antoñanzas, W. Edmunds, 2002, PharmacoEconomics.

[Recurrent respiratory infections in patients with chronic obstructive bronchitis: medical treatment and costs].

F. Fagnani, M. Morales, S. Brin, 1996, Revue des maladies respiratoires.

Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection.

I. Durand, B. Khoshnood, M. Pechevis, 2003, Vaccine.

An outbreak of hepatitis A in a French day-care centre and efforts to combat it

B. Detournay, Y. Buisson, A. Lafuma, 1997, European Journal of Epidemiology.

Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study

P. Vieregge, G. Berdeaux, C. Clarke, 2005, European journal of neurology.

Donepezil for the Treatment of Mild to Moderate Alzheimer’s Disease in France: The Economic Implications

F. Fagnani, L. Traykov, Latchezar Traykov, 2003, Dementia and Geriatric Cognitive Disorders.

Socio-economic planning: legislative measures for improvement of the nutritional status of the mother/child dyad.

M. Manciaux, M. Péchevis, 1979 .

[Maternal mortality and referral maternities in Morocco: how to (re)motivate professionals?].

J. Cook, M. Péchevis, H. Fernández, 1999, Sante publique.

Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients.

F. Fagnani, B. Detournay, C. Pribil, 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.